In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|March 7, 2019
Dolutegravir-Based Regimens: The Botswana Beat Cohort Study's 'Encouraging' Results
Author(s)Contagion® Editorial Staff
Ava Avalos, MD, discusses the "encouraging" 12-month outcomes from the Botswana Beat Cohort study, which employs a dolutegravir-based regimen.
Advertisement
Segment Description: Ava Avalos, MD, director of the Careena Centre for Health in Botswana, discusses the "encouraging" 12-month outcomes from the
Interview transcript: (modified slightly for readability)
Contagion®: What is your bottom-line message for clinicians regarding dolutegravir-based regimens?
Ava Avalos, MD: "The information that we're sharing is very, very encouraging. People do incredibly well, [there are] very, very few toxicities, very, very little loss to follow-up, and I think less than 2% deaths. Overall in the national program in Botswana we have beautiful outcomes. We have over 95,000 patients on DTG. We have less than 2% adverse events. Medication is tolerated incredibly well and very, very high viral load suppression.So, really, I think Botswana is one of the countries that can serve as an example of what treatment programs can do around the world and how much easier it is for us and how much better it is for patients to give less toxic, better-tolerated medications."
The poster, “
Advertisement
Related to this article
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement
Trending on Contagion Live
1
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
2
Evaluating Ebola Vaccine Against Current Bundibugyo Species
3
How The Food Safety Surveillance Infrastructure Works in the US
4
Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection
5